NCT01854216View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Healthy
Interventions
DRUG

Rotigotine transdermal patch 1mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours

DRUG

Rotigotine transdermal patch 2 mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours

DRUG

Rotigotine transdermal patch 4 mg / 24 hours

Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours

Trial Locations (1)

Unknown

1, Neuss

All Listed Sponsors
lead

UCB BIOSCIENCES GmbH

INDUSTRY

NCT01854216 - Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter